Table 2.

MSC from AT after osteodifferentiation and licensing by IFN-γ and TNF-α do not induce PBMC proliferation in allogenic conditions.

R : Sa  ratio	MSC-AT	MSC-AT IFN-γ/TNF-α	Os-MSC-AT	Os-MSC-AT IFN-γ/TNF-α
1 : 0.5	5.6 ± 1.0b	7.2 ± 3.1	1.1 ± 0.2	0.9 ± 0.6
1 : 0.25	5.5 ± 1.5	5.2 ± 2.6	1.3 ± 0.3	0.8 ± 0.5
1 : 0.12	5.3 ± 1.5	4.7 ± 2.9	1.0 ± 0.3	1.1 ± 0.8
1 : 0.06	5.3 ± 2.0	5.5 ± 3.0	1.0 ± 0.2	1.3 ± 1.0
1 : 0.03	4.6 ± 1.1	3.9 ± 2.0	1.4 ± 0.3	1.8 ± 1.3

^aPBMC from healthy individuals were used as responder cells towards AT-derived MSCs pretreated with IFN-γ and TNF-α (MSC-AT IFN-γ/TNF-α) or not (MSC-AT) as stimulating cells at various responder : stimulator (R : S) ratios. Similar experiments were performed with AT-derived MSCs committed to osteodifferentiation process and pretreated with IFN-γ and TNF-α (Os-MSC-AT IFN-γ/TNF-α) or not (Os-MSC-AT) as stimulating cells.

^bData are mean ± s.e.m. of alloproliferation percentage obtained with 4 and 3 distinct healthy donors for MSC-AT and Os-MSC-AT experiments, respectively. This percentage is calculated considering PBMC stimulated with LCL* as 100% alloproliferation.